Literature DB >> 12822172

The Genesis stent: A new low-profile stent for use in infants, children, and adults with congenital heart disease.

Thomas J Forbes1, Edwin Rodriguez-Cruz, Zahid Amin, Lee N Benson, Thomas E Fagan, William E Hellenbrand, Larry A Latson, Phillip Moore, Charles E Mullins, Julie A Vincent.   

Abstract

Placement of intravascular stents that can reach adult size in infants and smaller children has been limited by the large profile and poor flexibility of currently available stents. In vitro and in vivo testing of the Genesis stent was performed to evaluate crimpability, predeployment flexibility, and radial strength. Comparisons were made to the Palmaz iliac and IntraStent (IS) LD stents. Nine physicians placed 30 Genesis stents in swine pulmonary and systemic arteries to evaluate stent deliverability/crimpability. Two swine were recovered and underwent a second catheterization 8 weeks later, where the stents (n = 8) were reexpanded to maximal size. Angiographic and intravascular ultrasound (IVUS) assessments were performed. In vitro testing revealed the Genesis stent to have superior crimpability, flexibility, and comparable radial strength to the Palmaz iliac stent, and superior crimpability and radial strength and comparable flexibility to the IS LD series. During in vivo testing, the physicians graded the Genesis stent superior to the Palmaz stent regarding crimpability and deliverability, and superior to the IS LD stent in regard to crimpability, and comparable to or superior in deliverability. In the chronic animals, the Genesis stent was expanded up to maximal diameter 8 weeks following implantation. Angiographic and IVUS revealed no fractures no in-stent restenosis. The Genesis stent can be easily delivered through smaller sheaths, which will facilitate their use in infants and smaller children with vascular stenosis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12822172     DOI: 10.1002/ccd.10547

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

1.  Ultra-high-pressure balloon angioplasty for treatment of resistant stenoses within or adjacent to previously implanted pulmonary arterial stents.

Authors:  Jessica Maglione; Lisa Bergersen; James E Lock; Doff B McElhinney
Journal:  Circ Cardiovasc Interv       Date:  2008-12-15       Impact factor: 6.546

2.  Effectiveness and safety of percutaneous transcatheter implantation of pulmonary arterial stent in congenital heart disease.

Authors:  Hong Ki Ko; Young-Hwue Kim; Jeong Jin Yu; Jae-Kon Ko; In-Sook Park; Dong-Man Seo; Tae-Jin Yun; Jeong-Jun Park; Wan Sook Jang
Journal:  Korean Circ J       Date:  2012-01-31       Impact factor: 3.243

3.  Quantification of local hemodynamic alterations caused by virtual implantation of three commercially available stents for the treatment of aortic coarctation.

Authors:  Sung Kwon; Jeffrey A Feinstein; Ronak J Dholakia; John F Ladisa
Journal:  Pediatr Cardiol       Date:  2013-11-21       Impact factor: 1.655

4.  Medium and long-term outcomes after bilateral pulmonary artery stenting in children and adults with congenital heart disease.

Authors:  Ismael Gonzalez; Damien Kenny; Shari Slyder; Ziyad M Hijazi
Journal:  Pediatr Cardiol       Date:  2012-07-28       Impact factor: 1.655

5.  Percutaneous stent placement in children weighing less than 10 kilograms.

Authors:  Ravi Ashwath; Daniel Gruenstein; Ernest Siwik
Journal:  Pediatr Cardiol       Date:  2007-11-29       Impact factor: 1.655

6.  In situ fracture of stents implanted for relief of pulmonary arterial stenosis in patients with congenitally malformed hearts.

Authors:  Doff B McElhinney; Lisa Bergersen; Audrey C Marshall
Journal:  Cardiol Young       Date:  2008-06-18       Impact factor: 1.093

7.  The role of the new Valeo stent in treating pulmonary artery stenoses in children with complex cardiac malformations: A report of two cases.

Authors:  Nikhil Sharma; Sebastian Goreczny
Journal:  Am J Case Rep       Date:  2014-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.